I believe they estimate Valve in Valve to be 30% of TAVR sales in future, isn’t it reassuring to know we have Dr Vinayak Bapat on our advisory board to help guide us.
”Finally, regarding the correct study of the bioprostheses, the “Valve-in-Valve” app developed in collaboration between the technology company UBQO and Dr. Vinayak Bapat is certainly one of the must-have tools for optimal planning of the ViV TAVR procedure[20].”
Ann: FDA Grants Expanded Approval for the DurAVR EFS, page-9
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$6.12 |
Change
-0.030(0.49%) |
Mkt cap ! $94.85M | |||
| Open | High | Low | Value | Volume |
| $6.21 | $6.21 | $6.00 | $16.53K | 2.704K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1000 | $6.01 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $6.08 | 240 | 1 |
View Market Depth
| Last trade - 15.46pm 25/06/2025 (20 minute delay) ? |
| AVR (ASX) Chart |